Michael Ryskin
Stock Analyst at B of A Securities
(1.39)
# 3,533
Out of 4,984 analysts
37
Total ratings
47.83%
Success rate
-2.09%
Average return
Main Sectors:
Stocks Rated by Michael Ryskin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Maintains: Neutral | $68 → $70 | $87.04 | -19.58% | 6 | Jun 25, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $535 → $475 | $645.65 | -26.43% | 3 | Apr 21, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Buy | $9 → $8 | $2.89 | +176.82% | 3 | Mar 3, 2025 | |
| ALGN Align Technology | Maintains: Underperform | $200 → $206 | $131.82 | +56.27% | 6 | Dec 13, 2024 | |
| GH Guardant Health | Maintains: Buy | $28 → $40 | $55.40 | -27.80% | 1 | Jul 18, 2024 | |
| ALIT Alight | Maintains: Buy | $10 → $9.5 | $3.44 | +176.16% | 1 | Jun 25, 2024 | |
| CERT Certara | Maintains: Buy | $27 → $24 | $11.55 | +107.79% | 2 | Aug 15, 2023 | |
| AVTR Avantor | Maintains: Buy | $27 → $24 | $12.71 | +88.83% | 2 | Jul 31, 2023 | |
| ZTS Zoetis | Maintains: Buy | $225 → $180 | $147.46 | +22.07% | 7 | Nov 4, 2022 | |
| RXRX Recursion Pharmaceuticals | Downgrades: Neutral | n/a | $4.84 | - | 2 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $52 | $19.11 | +172.11% | 2 | Nov 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $17 → $10 | $2.70 | +270.37% | 2 | Nov 10, 2021 |
Tempus AI
Jun 25, 2025
Maintains: Neutral
Price Target: $68 → $70
Current: $87.04
Upside: -19.58%
IDEXX Laboratories
Apr 21, 2025
Maintains: Neutral
Price Target: $535 → $475
Current: $645.65
Upside: -26.43%
Maravai LifeSciences Holdings
Mar 3, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.89
Upside: +176.82%
Align Technology
Dec 13, 2024
Maintains: Underperform
Price Target: $200 → $206
Current: $131.82
Upside: +56.27%
Guardant Health
Jul 18, 2024
Maintains: Buy
Price Target: $28 → $40
Current: $55.40
Upside: -27.80%
Alight
Jun 25, 2024
Maintains: Buy
Price Target: $10 → $9.5
Current: $3.44
Upside: +176.16%
Certara
Aug 15, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $11.55
Upside: +107.79%
Avantor
Jul 31, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $12.71
Upside: +88.83%
Zoetis
Nov 4, 2022
Maintains: Buy
Price Target: $225 → $180
Current: $147.46
Upside: +22.07%
Recursion Pharmaceuticals
Apr 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $4.84
Upside: -
Nov 11, 2021
Downgrades: Neutral
Price Target: $80 → $52
Current: $19.11
Upside: +172.11%
Nov 10, 2021
Downgrades: Underperform
Price Target: $17 → $10
Current: $2.70
Upside: +270.37%